

SUBJECTIVE SYMPTOMS AND UPPER LIMBS FUNCTIONALITY AFTER COMPRESSIVE BANDAGE IN PATIENTS WITH SEROMA AFTER BREAST CANCER SURGERY

Clarice Gomes Chagas Teodózio¹; Erica Alves Nogueira Fabro²; Luiz Claudio Santos Thuler;³ Anke Bergmann⁴

¹Author. National Cancer Institute. ²Co-Author. National Cancer Institute.

³Second Advisor. National Cancer Institute. ⁴ First Advisor. National Cancer Institute.

INTRODUCTION

Breast cancer is nowadays a public health problem. Treatment varies according to the staging and the biological characteristics of the disease. One of the most common complications are seroma, which is a collection of serous fluid that develops under cutaneous flaps or in the dead space after a surgical approach and is usually treated with aspiration puncture. The use of compression bandaging for the treatment of seroma is a new clinical approach, but still little explored in the scientific literature

OBJECTIVE

To evaluate the incidence of subjective symptoms (pain, discomfort) and upper limb function due to the use of compression bandaging in patients with seroma secondary to surgical treatment for breast cancer.

METHODS

This is a medical device pilot study in women submitted to surgical treatment for breast cancer at Hospital do Câncer III / National Cancer Institute. Those that develop seroma will be included. The intervention will be performed by applying the compression bandage over the seroma region for approximately four days, when they will return to the physiotherapy outpatient clinic for suspension of the intervention and reassessment. The socio-demographic data, life habits, evaluation of symptoms and functionality will be collected by interview and upper limb dysfunction questionnaires. The application of the questionnaire on feeling / sensation reported by women throughout the intervention period will be performed at the end of seroma treatment. Our hypothesis is that will be possible to identify the safety of the use of compressive bandage, allowing a new option of non-invasive therapy for the treatment of seroma in patients submitted to surgery for breast cancer.

PERSPECTIVES

Currently, 19 patients were included, of those 17 completed the intervention and 2 are in follow-up. It will require 40 patients to complete the study that will be included until December 2017.